Cargando…
Cutaneous Lymphoma and Antibody-Directed Therapies
The introduction of monoclonal antibodies such as rituximab to the treatment of cancer has greatly advanced the treatment scenario in onco-hematology. However, the response to these agents may be limited by insufficient efficacy or resistance. Antibody–drug conjugates are an attractive strategy to d...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10045448/ https://www.ncbi.nlm.nih.gov/pubmed/36975368 http://dx.doi.org/10.3390/antib12010021 |
_version_ | 1784913605814124544 |
---|---|
author | Sernicola, Alvise Ciolfi, Christian Miceli, Paola Alaibac, Mauro |
author_facet | Sernicola, Alvise Ciolfi, Christian Miceli, Paola Alaibac, Mauro |
author_sort | Sernicola, Alvise |
collection | PubMed |
description | The introduction of monoclonal antibodies such as rituximab to the treatment of cancer has greatly advanced the treatment scenario in onco-hematology. However, the response to these agents may be limited by insufficient efficacy or resistance. Antibody–drug conjugates are an attractive strategy to deliver payloads of toxicity or radiation with high selectivity toward malignant targets and limited unwanted effects. Primary cutaneous lymphomas are a heterogeneous group of disorders and a current area of unmet need in dermato-oncology due to the limited options available for advanced cases. This review briefly summarizes our current understanding of T and B cell lymphomagenesis, with a focus on recognized molecular alterations that may provide investigative therapeutic targets. The authors reviewed antibody-directed therapies investigated in the setting of lymphoma: this term includes a broad spectrum of approaches, from antibody–drug conjugates such as brentuximab vedotin, to bi-specific antibodies, antibody combinations, antibody-conjugated nanotherapeutics, radioimmunotherapy and, finally, photoimmunotherapy with specific antibody–photoadsorber conjugates, as an attractive strategy in development for the future management of cutaneous lymphoma. |
format | Online Article Text |
id | pubmed-10045448 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-100454482023-03-29 Cutaneous Lymphoma and Antibody-Directed Therapies Sernicola, Alvise Ciolfi, Christian Miceli, Paola Alaibac, Mauro Antibodies (Basel) Review The introduction of monoclonal antibodies such as rituximab to the treatment of cancer has greatly advanced the treatment scenario in onco-hematology. However, the response to these agents may be limited by insufficient efficacy or resistance. Antibody–drug conjugates are an attractive strategy to deliver payloads of toxicity or radiation with high selectivity toward malignant targets and limited unwanted effects. Primary cutaneous lymphomas are a heterogeneous group of disorders and a current area of unmet need in dermato-oncology due to the limited options available for advanced cases. This review briefly summarizes our current understanding of T and B cell lymphomagenesis, with a focus on recognized molecular alterations that may provide investigative therapeutic targets. The authors reviewed antibody-directed therapies investigated in the setting of lymphoma: this term includes a broad spectrum of approaches, from antibody–drug conjugates such as brentuximab vedotin, to bi-specific antibodies, antibody combinations, antibody-conjugated nanotherapeutics, radioimmunotherapy and, finally, photoimmunotherapy with specific antibody–photoadsorber conjugates, as an attractive strategy in development for the future management of cutaneous lymphoma. MDPI 2023-03-03 /pmc/articles/PMC10045448/ /pubmed/36975368 http://dx.doi.org/10.3390/antib12010021 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Sernicola, Alvise Ciolfi, Christian Miceli, Paola Alaibac, Mauro Cutaneous Lymphoma and Antibody-Directed Therapies |
title | Cutaneous Lymphoma and Antibody-Directed Therapies |
title_full | Cutaneous Lymphoma and Antibody-Directed Therapies |
title_fullStr | Cutaneous Lymphoma and Antibody-Directed Therapies |
title_full_unstemmed | Cutaneous Lymphoma and Antibody-Directed Therapies |
title_short | Cutaneous Lymphoma and Antibody-Directed Therapies |
title_sort | cutaneous lymphoma and antibody-directed therapies |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10045448/ https://www.ncbi.nlm.nih.gov/pubmed/36975368 http://dx.doi.org/10.3390/antib12010021 |
work_keys_str_mv | AT sernicolaalvise cutaneouslymphomaandantibodydirectedtherapies AT ciolfichristian cutaneouslymphomaandantibodydirectedtherapies AT micelipaola cutaneouslymphomaandantibodydirectedtherapies AT alaibacmauro cutaneouslymphomaandantibodydirectedtherapies |